GO Therapeutics Enters into a License Agreement with $RHHBY for New Glycotargeting Bispecific Cancer Treatment.$9M upfront and up to $186M in milestones https://www.businesswire.com/news/home/20181002005476/en/Therapeutics-Enters-License-Agreement-Roche-N

08:03 EDT 2 Oct 2018 | Odi Bruckman

GO Therapeutics Enters into a License Agreement with $RHHBY for New Glycotargeting Bispecific Cancer Treatment.$9M upfront and up to $186M in milestones https://www.businesswire.com/news/home/20181002005476/en/Therapeutics-Enters-License-Agreement-Roche-New-Glycotargeting …

More From BioPortfolio on "GO Therapeutics Enters into a License Agreement with $RHHBY for New Glycotargeting Bispecific Cancer Treatment.$9M upfront and up to $186M in milestones https://www.businesswire.com/news/home/20181002005476/en/Therapeutics-Enters-License-Agreement-Roche-N"